Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + leucovorin + methotrexate + procarbazine + rituximab + vincristine
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
This is a combination chemotherapy regimen containing cytarabine (a nucleoside analog), leucovorin (a reduced form of folate), methotrexate (an antimetabolite), procarbazine (an alkylating agent), rituximab (a monoclonal antibody targeting CD20), and vincristine (a vinca alkaloid). This combination is likely used in the treatment of certain types of lymphoma, particularly B-cell lymphomas. The regimen combines different mechanisms of action to target cancer cells through multiple pathways.
02
Targets
CD20 (B-lymphocyte antigen CD20)DNADNA polymerase familyDHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cytarabine + leucovorin + methotrexate + procarbazine + rituximab + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + leucovorin + methotrexate + procarbazine + rituximab + vincristine.